Introduction
The molecular phenotype of allograft rejection is of considerable interest as a prototypic adaptive immune response (1) (2) (3) . Rejection consists of two distinct diseases: T cell-mediated rejection (TCMR) and antibodymediated rejection (ABMR). Understanding clinical rejection syndromes requires human biopsies: Experimental models can examine aspects of TCMR (4) and ABMR (5, 6 ), but they do not simulate the spectrum of human rejection because of species differences (e.g. lack of the CD16a fold change receptor on mouse NK cells) and the limited time course of animal models. Annotating the molecular changes associated with rejection in biopsies depends on accurate histology classification-an ongoing challenge. Histologic lesions of rejection are not highly specific, and their interpretation requires guidelines to specify when the lesions permit the diagnosis of rejection. Moreover, the histologic guidelines are continually evolving, making the published literature difficult to interpret. In kidney transplantation, for example, the term acute rejection for decades meant only TCMR (7) .
Microcirculation lesions of ABMR were recognized in 1990 (8) , but formal criteria for ABMR were published only in 2003 (9) and, unfortunately, missed the majority of ABMR by requiring capillary immunostaining for complement factor C4d. Acknowledging C4d-negative ABMR reclassified many biopsies (10, 11) and now permits histologic classification of most biopsies as rejection (TCMR, ABMR, or mixed) or no rejection, although still leaving some biopsies unclassified ("borderline").
Identifying molecules associated with histologic rejection in biopsies requires binary algorithms that compare a positive class with a negative class. The positive comparator can be ABMR, TCMR, or all rejection (ABMR, TCMR, and mixed). The negative comparator can be biopsies with minimal abnormalities (2, 12, 13) or all biopsies with no rejection, including injured and diseased biopsies (14) . In defining rejection-associated transcripts, we prefer to use all biopsies with no rejection as the negative comparator (15) (16) (17) . This helps neutralize the effects of nonspecific injury, particularly the universal stress of donation and implantation. Injury activates a complex time-dependent response-to-wounding program that shares molecular features with rejection, including inflammation and remodeling of the matrix and microcirculation (18) . Tissue injury, for example, evokes appearance of interferon c (IFNG)-inducible transcripts and transcripts expressed in infiltrating inflammatory cells (18) ; therefore, transcripts prominent in rejection may also be increased in some nonrejecting transplants (19) and native kidneys with diseases (20) .
The present study aimed to create a comprehensive picture of the transcript changes characteristic of allograft rejection using multiple algorithms and, ultimately, to generate a single list of the top rejection-associated transcripts, including those universal for all rejection and those selective for ABMR or TCMR. We also studied whether features highly associated with rejection were found in some transplants with no histologic rejection or in native kidneys with diseases. The goal was a unified view of the molecular changes in organ allograft rejection as a function of algorithm, case mix, and histologic classification.
Note that the implications of these findings for diagnostic accuracy will be explored in a separate paper (in preparation).
Materials and Methods
Indication biopsies were collected in two consecutive prospective multicenter studies of consented patients: 403 from the Genome Canada study (discovery set) and 300 from the International Collaborative Microarray study (INTERCOM; validation set) (16, 17, 21, 22) . Details of the combined set (N = 703) were described previously (23) . The discovery and validation sets had similar case mixes. Patients gave consent under protocols approved by local institutional review boards (23) . All indication biopsies were included to represent all rejection, disease, and injury states commonly affecting kidney transplants (17) .
Histologic biopsy assessment
Biopsy processing and histologic classification were performed as standard of care for the center, as outlined previously (21, 22) . All centers followed the latest Banff histology system, including C4d-negative ABMR (11) .
Microarray analyses
RNA extraction, labeling, and processing of the HG_U133_Plus_2.0 GeneChip (Affymetrix, Santa Clara, CA) were described previously (16) . The correction factor was used for the normalization of the combined set to account for batch effects (23) . Microarray data sets were published previously (16, 17, 21, 22) and are on the Gene Expression Omnibus site: Genome Canada (GSE36059) and INTERCOM (GSE48581).
Analysis of transcript expression using the cell culture panel 
IFNG and rejection-induced transcripts
IFNG and rejection-induced transcripts (GRITs; http://atagc.med. ualberta.ca/Research/GeneLists/) originated as human orthologs of mouse GRITs (19) plus HLA-related and other transcripts induced by IFNG in human cell cultures. GRITs used in this study had to pass the interquartile range (IQR) filter in the combined biopsy set and had expression that increased more than fourfold by IFNG treatment and a hybridization signal >200 after treatment of macrophages, HUVECs, or RPTECs by IFNG.
Statistical analysis
Rejection included ABMR (C4d-positive and C4d-negative), TCMR, and mixed ABMR/TCMR. To represent nonrejection injuries and diseases, the "everything else" (EE) group included all other biopsies. Excluding borderline biopsies for class comparisons (n = 89) left 127 biopsies with rejection and 233 without rejection in the discovery set, 78 biopsies with rejection and 176 without rejection in the validation set, and 205 biopsies with rejection and 409 with no rejection in the combined set. Binary group comparisons were done with a moderate Bayes t-test (25) and Benjamini-Hochberg false discovery rate.
External data set
The external data set contained microarray files from HG U133A_2 arrays representing microdissected native control kidneys (n = 20) and kidneys with chronic kidney disease (CKD) from patients with diabetes (n = 18) (20) . We compared these two groups by one-way analysis of variance.
Union of the rejection transcripts
The union included rejection-associated transcripts from the three main algorithms: rejection versus EE (RvEE), ABMR versus EE (AvEET), and TCMR versus EE (TvEEA). Selecting 200 probe sets with IQR >0.4 (19 920 probe sets) from each algorithm by p-value and removing overlaps yielded 454 probe sets.
Pathway analysis
Transcripts were analyzed using Ingenuity Pathway Analysis (IPA; Qiagen, Redwood City, CA) with a focus on the top canonical pathway and upstream regulator (18) . The DAVID tool (26) tested Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, and the gene ontology (GO) term molecular function. The most significant IPA, KEGG pathways, and GO terms were selected by corrected p-values.
Results
The biopsy population The combined set included 205 biopsies with histologic rejection: 110 ABMR (30 C4d-positive and 80 C4d-negative), 28 mixed, and 67 TCMR; 89 ambiguous biopsies designated borderline; and 409 biopsies with no histologic rejection. These biopsies represent a comprehensive collection of all rejection and nonrejection phenotypes observed in indication biopsies 3 days to 35 years after transplant, without exclusions. The mean time of biopsy after transplant was 1551 days (4.24 years), with a median of 571 days (1.56 years). All biopsies were classified using the latest histology guidelines that include C4d-negative ABMR (11) .
The list of illustrations, as first cited in the text, is presented in Table S1 .
Developing the algorithms For clarity in designating algorithms, histologic diagnoses were given abbreviations ( Figure 1 ). Borderline biopsies were excluded from all rejection algorithms because they had not been assigned to a rejection or no rejection class. Eight algorithms are shown in Figure 1 , each designated as a positive class versus a negative class. The reference tables show the top 100 nonredundant (by pvalue) and annotated transcripts for each algorithm (Table S2 ). Nonredundant transcript means that when multiple probe sets represent one gene, only the one with the best p-value is selected.
The research plan is summarized in Table 1 .
The universal algorithm: rejection versus EE (RvEE): We previously reported an RvEE algorithm, before recognizing C4d-negative ABMR (15) . The RvEE algorithm was thus rederived in the current population (N = 703), acknowledging C4d-negative ABMR and permitting comparison to the other algorithms.
RvEE in discovery and validation sets: RvEE molecular changes were similar in the discovery and validation sets, both fold change ( Figure 2A ) and association strength (p-value) ( Figure 2B ), as noted previously for the TvEEA (24) and AvEET algorithms (27) . Consequently, when the same case mix, phenotyping system, algorithm, and technology platform are used, the molecular phenotype is strongly conserved. The exact rank of the strongly associated transcripts selected by p-value shows some variation between the discovery and validation sets ( Figure 2B ), as expected when selecting from 54 000 probe sets. The RvEE landscape: Most of the top 30 rejectionassociated transcripts, as in our earlier analysis (15) , were IFNG-inducible (GRITs) ( Figure 2C , green symbols; Table S3 ) (19) , and most of the 315 annotated GRITs (291 of 315, 92%) were highly associated with rejection in the RvEE algorithm (false discovery rate <0.05).
The previously described top TCMR-selective (TvEEA) and ABMR-selective (AvEET) transcripts (24, 27 ) (red and blue symbols, respectively, in Figure 2C ) had moderate association strength with RvEE (p = 10 À37 to p = 10 À12 ), less than the top RvEE transcripts (p = 10 À55 to p = 10 À45 ).
Transcripts representative of the inflammasome (yellow symbols) were not prominent in RvEE because they are strongly associated with TCMR (24) but not ABMR (27) . The top inflammasome transcript in RvEE, CASP1 (p = 10 À38 ), is inducible by IFNG and is a green symbol in Figure 2C .
Immunoglobulin transcripts (black symbols) displayed high fold change but low association strength. Their primary association is with atrophy-fibrosis, regardless of cause, resulting in weak association with rejection (28).
Many transcripts were decreased in biopsies with rejection (e.g. kidney transporters; magenta symbols in Figure 2C ), but their association with rejection was weak because tissues lose transcripts related to function and metabolism in many disease states, reflecting parenchymal injury (acute kidney injury [AKI]) (29) and atrophy (18, 30) .
Expression of RvEE transcripts in cell lines and pathway analysis: In a previously described cell panel (24) (Figure 3 ), 27 of 30 top RvEE transcripts (90%) were IFNG inducible in macrophages and/or in HUVECs and RPTECs. CCL4, expressed in effector T cells, NK cells, and dendritic cells, was moderately IFNG inducible in macrophages although did not meet criteria for annotation as a GRIT. The three non-IFNG-inducible transcripts-KLRD1 (CD94), NKG7 (natural killer cell granule protein), and PRF1 (perforin)-were expressed in both NK cells and effector T cells (CD4 + and CD8 + ).
Pathway analysis confirmed the dominance of IFNG effects in RvEE. In IPA, the main upstream regulator of the top 300 RvEE-associated transcripts was IFNG (activation status z-score = 8.6) ( Table S4 ). The top IPA canonical pathway, KEGG pathway, or GO term for the 300 RvEE-associated transcripts by p-values was antigen presentation/processing (Table S4) , reflecting IFNGeffects on MHC and related genes.
Sharing of transcripts between universal (RvEE) and selective (AvEET, TvEEA) algorithms: As previously reported, the top TvEEA transcripts reflected effector T cell activation and macrophage-dendritic cell activation, including immune checkpoint molecules (31) , and the top AvEET transcripts reflected NK cell localization and endothelial injury (27) .
Deriving the universal RvEE transcripts permitted us to compare the top transcripts in the universal versus selective algorithms (Table 2 ). There was no overlap between the top 30 TvEEA and AvEET transcripts, and only one (GBP5) was shared between TvEEA and RvEE. There was more sharing between RvEE and AvEET: PLA1A, CCL2, CXCL10, CXCL11, and KLRD1.
Of interest, the top TvEEA transcripts that were IFNG inducible (e.g. ANKRD22, RARRES3) did not overlap the top RvEE or AvEET transcripts that were IFNG inducible, indicating that some IFNG effects are relatively selective for TCMR.
Most top AvEET transcripts were expressed either in endothelial cells or NK cells. NK-expressed AvEET transcripts included CD16a-inducible molecules such as CD160 (32, 33) , cytotoxic molecules such as PRF1, and membrane receptors such as KLRD1.
Comparing ranking between algorithms: Table 3 shows respective rankings of the top rejectionassociated transcripts. The top 10 RvEE transcripts ranked high in AvEET (median rank 58) and TvEEA (median rank 412). The top 10 AvEET transcripts ranked high in RvEE (median rank 489) but very low in TvEEA (median rank 26 489). The top 10 TvEEA transcripts ranked high in RvEE (median 585) but very low in AvEET (median rank 34 385). Consequently, top RvEE transcripts were related to both AvEET and TvEEA, but top AvEET and TvEEA transcripts were unrelated to each other, confirming their selectivity.
Direct class comparison between TCMR and ABMR:
The TvA algorithm: Class comparison of TCMR to ABMR (TvA) by p-value (Table 4 ) was expected to yield top transcripts that were a mix of TCMR-and ABMRselective transcripts but, in fact, was completely dominated by TCMR transcripts because TCMR has stronger signals and p-values. The top TvA transcripts all ranked high in TvEEA (median 117) and RvEE (median rank 1706) but low in AvEET (median rank 28 589). Of interest, many top transcripts in TvA were increased in myeloid cells (dendritic cells and macrophages; e.g. ADAMDEC1, CCL18, and CXCL13), underscoring the prominence of myeloid cells in TCMR but not ABMR.
ABMR occurs later than TCMR and has more timedependent changes, including atrophy-fibrosis. When we examined the transcripts increased by fold change in ABMR versus TCMR (not shown), some were like AvEET transcripts, but many were related to atrophy scarring (e.g. immunoglobulin genes) (18) . Consequently, the transcripts selective for ABMR were better identified by AvEET than TvA because inclusion of many injured but nonrejecting biopsies in the negative comparator in AvEET neutralizes the effects of time and atrophyfibrosis, unlike the TvA comparison.
Importance of case mix for identifying selective transcripts:
Comparing eight algorithms: We explored how case mix in the comparator of the eight class-comparison algorithms influenced the top transcripts selected, particularly the ABMR-or TCMRselective transcripts (Table 5) . Selectivity, that is, decreasing overlap of transcripts with the universal RvEE algorithm, varied with the negative class comparator. Selectivity for ABMR increased in the following order: RvEE, AvN, AvEE, AvEET. Selectivity for TCMR increased in the following order: RvEE, TvN, TvEE, TvEEA. High selectivity required that both EE and the other rejection class be included in the comparator to avoid the universal transcripts.
The impact of case mix implies that if selective transcripts are to be annotated in a biopsy population, TCMR and ABMR must be both abundant and accurately classified.
Random variation in probe sets ranked in the top 100 by p-value: As noted in Figure 2B , when selecting from 54 000 probe sets in highly similar biopsy populations by p-value, random variation in rank will occur among highly associated transcripts. We examined the stability of the probe sets ranked in the top 100 in each algorithm by randomly dividing the 703 biopsies into two halves 100 times and determining the number of times each top 100 probe set in one half was ranked in the top 100 in the other half (Table S5) . Considerable variation occurred between halves of the biopsy set. The most stable list was RvEE (62.9% reproduced) and the least stable was TvA (20.4% reproduced). ABMR algorithms were more stable than TCMR algorithms, either because there were more ABMR biopsies or because more probe sets were strongly associated with TCMR and competing for the top 100 positions.
The case mix in the negative comparator affects the biology represented by the top transcripts: The biological annotation changed as the negative class was simplified (Table 6 ): ABMR algorithms lost endothelial and NK cell transcripts, TCMR algorithms lost effector T cell transcripts, and both acquired universal IFNG-inducible transcripts. The case mix in the negative class thus strongly influences the biology represented in the top transcripts. In particular, the inclusion of TCMR in the negative comparator for the ABMR-selective comparator was necessary to elicit the endothelial transcripts as top features of ABMR because it canceled the universal features.
Expression of rejection-associated transcripts in biopsies with no rejection and in native CKD: We examined mean expression of the top 30 RvEE, AvEET, and TvEEA transcripts in individual biopsies assigned histologic diagnoses of TCMR, ABMR, AKI, or These ranks correspond to full lists of probe sets, without correction for their redundancies at the gene level.
atrophy-fibrosis or in normal transplants compared with histologically normal kidney tissue from nephrectomies (not transplants) (Figure 4 ; each dot represents the mean expression in one biopsy; individual comparisons are analyzed statistically in Table S6 ). Mean expression of RvEE transcripts was increased in TCMR and ABMR and not in normal kidney tissue but also was increased in transplant biopsies with other diagnoses ( Figure 4A ). Similarly, AvEET transcripts ( Figure 4B ) and TvEEA transcripts ( Figure 4C ) had high mean expression in histologic ABMR and TCMR, respectively, and low expression in normal kidney tissue but also had increased expression in some transplant biopsies without rejection, particularly abnormal biopsies. Note, for example, the increased expression of top AvEET transcripts in many biopsies with histologic TCMR (Figure 4B ), indicating that ABMR-selective genes do not truly separate ABMR from TCMR. Note that the genes do not clearly separate either TCMR from ABMR or TCMR or ABMR from IFTA.
Expression of the top 10 individual transcripts further illustrates this point (Table 7) . Although highly expressed in the appropriate positive class, the top 10 RvEE, AvEET, and TvEEA transcripts had higher mean expression in some biopsies in the negative comparators. The reasons for the lack of specificity include errors in histologic diagnoses, as discussed previously (16, 17, 23) , but also reflects sharing of molecules between disease processes.
We studied whether the top rejection transcripts were increased in CKD (20) by examining a published data set including kidneys from diabetic patients with CKD and histologically normal kidneys. Virtually all rejection transcripts were significantly increased in CKD compared with normal native kidneys by either the fold change Figure S1 ). We conclude that strong associations with positive comparators do not preclude increased expression in some biopsies of the negative comparator, probably because rejection shares mechanisms with innate immunity and matrix and microcirculation remodeling of the response-to-wounding programs also seen in the native kidney chronic diseases.
A union set of rejection-associated probe sets for unsupervised analysis: We created a union of topranked rejection-associated transcripts by combining top universal RvEE transcripts with top ABMR-and TCMRselective transcripts, choosing the top 200 by p-value from each (see Methods). Eliminating overlaps left a union set of 453 rejection transcripts ( Figure 5A ; Table S7 ). RvEE, TvEEA, and AvEET were selected because they best captured both selective and shared transcripts; the TvEE, TvN, AvEE, AvN added little.
In principal component analysis, expression of the union rejection probe sets separated the 703 biopsies (no exclusions): All rejection biopsies deviated to the right (PC1), and biopsies with ABMR (blue) and TCMR (red) transcripts separated in PC2 ( Figure 5B ). Some borderline biopsies (orange) distributed like ABMR or TCMR biopsies, although most distributed like nonrejection.
The correlation of the expression of each union rejection probe set with PC1 and PC2 of the biopsies is shown in The main algorithm RvEE is shaded. Numbers in columns and rows indicate how many probe sets are shared by a given combination of two algorithms. Note that shared probe sets can be found in more than one algorithm pair, and the sharing can vary from 100 to 0. ABMR, antibody-mediated rejection; AvEE, ABMR versus everything else excluding TCMR; AvEET, ABMR versus everything else including TCMR; AvN, ABMR versus normal transplant biopsies; RvEE, rejection versus everything else; TCMR, T cell-mediated rejection; TvEE, TCMR versus everything else excluding ABMR; TvEEA, TCMR versus everything else including ABMR; TvA, TCMR versus ABMR; TvN, TCMR versus normal transplant biopsies.
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Including CCL4 as interferon c inducible, although it is expressed in T and NK cells. DLGAP5 is also expressed in T cells.
6
BUB1 and NCAPG are also expressed in endothelium. Figure 5C . Almost all union transcripts correlated with PC1 (x-axis), particularly the universal RvEE probe sets. AvEET (blue) and TvEEA (red) correlated and anticorrelated with PC2, respectively.
Discussion
This study presents a comprehensive picture of the molecular changes associated with rejection and the elements that determine top ranking. The associations are dependent on four elements: measurement platform, case mix, class-comparison algorithms, and histology classification. When these elements are held constant, the molecular phenotype is highly conserved in different biopsy sets. The strongly associated RvEE, AvEET, and TvEEA transcripts were reproducible when the four elements were maintained, although the exact ranking of pvalues among 54 000 probe sets varied somewhat, as expected when many strongly associated features are competing. The biology represented by the top transcripts differed by algorithm: RvEE transcripts reflected IFNG effects and shared T/NK transcripts, TvEEA transcripts reflected accumulation and activation of effector T cells and myeloid cells, and AvEET transcripts reflected NK cell localization and endothelial injury. Selective features were elicited only when the other rejection phenotype was included in the negative comparator, underscoring the importance of case mix and accurate distinction between TCMR and ABMR. Direct comparison of top transcripts differing between ABMR and TCMR by pvalue yielded only TCMR-selective transcripts because TCMR is a stronger molecular signal. No single algorithm produced a complete picture of the molecular phenotype and thus potential disease mechanisms. The multiple algorithm approach makes possible a union set of strongly associated rejection transcripts that allows unsupervised reassessment of biopsy classes and their relationship with histology.
Strong associations do not mean complete specificity:
The top RvEE, TvEEA, and AvEET transcripts were often somewhat increased in transplant biopsies without histologic diagnoses of rejection compared with normal nontransplant kidney tissue. Although some of this is due to errors in histologic diagnoses of rejection, as noted previously (16, 17, 23) , most is probably real expression of rejection molecules in other processes such as biopsies with atrophy-fibrosis. This does not mean that most transplants have unrecognized rejection; similar changes occur in native kidneys with CKD due to diabetes. The tissue response-to-wounding programs activate innate immunity (inflammation) and matrix and microcirculation remodeling programs that share transcripts with rejection (18) . Donation and implantation-even with live donationwounds all organ transplants, and infections, diseases, drug toxicity, and previous rejection will all add their effects. The limited specificity of rejection transcripts has implications for molecular diagnostics, namely, that using single genes or the mean of a list of rejection-associated genes with a cutoff specifying positive versus negative is potentially misleading. The diagnostic issues will be analyzed in a separate paper (in preparation).
IFNG effects are inherent to all rejection because key effector cells in TCMR and ABMR share cognate recognition systems that release IFNG: a/b TCRs in effector T cells in TCMR (24) and CD16a (FCGR3A) fold chain receptors in NK cells in ABMR (27) . CD16a-activated NK cells resemble TCR-activated effector T cells (34) , with phosphorylation of Syk and Zap70 by Src-family kinases (e.g. Lck) (35) , calcium-dependent activation of calcineurin (36) and of the SOS/RAS/MED/ERK axis (37) , and degranulation (38) (39) (40) (41) as well as sharing transcription factors that induce transcription of nuclear factor of activated T cells 1 and 2, activator protein 1 and interferon gamma and other cytokines (42, 43) .
Although the universal association of IFNG-inducible transcripts with rejection invites targeting of IFNG to control rejection, experimental models warn that IFNG has potentially protective as well as harmful effects in rejection. IFNG could promote TCMR or ABMR, for example, by inducing MHC products or synergizing with tumor Comparison between control versus diabetes plus CKD in external data set (20) . Figure 4 . ABMR, antibody-mediated rejection; AvEET, ABMR versus everything else including TCMR; EE, everything else; RvEE, rejection versus everything else; TCMR, T cell-mediated rejection; TvEEA, TCMR versus everything else including ABMR.
necrosis factor superfamily members to produce cytotoxic effects (44) (45) (46) . But when IFNG actions on donor tissue are prevented by using IFNG KO hosts (47) or donor organs with disrupted genes for IFNG receptors (48, 49) or interferon regulatory factor 1 (50), graft destruction is accelerated, with early ischemic necrosis and microcirculation congestion. Consequently, some IFNG action in vascularized allografts may stabilize the microcirculation during TCMR, possibly because IFNG induces elements of the checkpoint mechanisms such as CD274 (PD-1 ligand) , potentially facilitating T cell exhaustion (51) . The lesson is that IFNG effects in rejection should be considered as a dynamic balance in which interventions may have unexpected consequences.
Because appreciating the ABMR-or TCMR-selective features is dependent on the composition of the negative class comparator, it is important to understand the case mix in biopsies used for studying rejection-associated molecular changes. The identification of features selective for ABMR by the AvEET algorithm, for example, was made possible by the many TCMR biopsies in the population (N = 703), which cancel out IFNG effects to expose NK and endothelial transcripts, and by including many abnormal nonrejection biopsies in the negative comparator. When TCMR and abnormal but nonrejecting biopsies were withheld (AvN), the top transcripts in AvN approached those in RvEE. The point is that studies of differences between ABMR and TCMR populations of biopsies, particularly when eliciting ABMR-selective features, must acknowledge differences in signal strength (TCMR greater than ABMR), and neutralize the greater atrophy scarring in the ABMR biopsy populations by including other abnormal biopsies in the negative comparator. Such considerations become important when we study other organ transplants in which the histologic classification of TCMR and ABMR is less secure and the case mix is less clear, such as heart, lung, and liver transplants.
The fact that direct comparison of ABMR versus TCMR yielded only transcripts related to TCMR, the stronger signal, does not mean that all biopsies histologically called ABMR are mixed ABMR/TCMR, because when we sort these biopsies by AvEET and TvEEA classifiers, ABMR and TCMR are truly distinct. The incidence of mixed rejection in this series is substantially lower than that from some other medical centers.
In discovering the molecular phenotype, it is important to understand the constraints of each measurement platform. The U133 arrays used, for example, have limitations in dynamic range and, even with 54 000 probe sets, miss many potentially important features such as alternative promoters and splicing variants that would be captured by platforms with greater dynamic range and coverage. Nevertheless, microarrays are a proven genomewide discovery platform that can identify a wide variety of altered genes, with durability in the market that provides reliable access to consistent materials and reagents to continue and reproduce the studies. Alternative discovery technologies like next-generation RNA sequencing have great promise but have not yet been compared with microarrays for either discovery or application in transplant biopsies.
The mapping of the universal and selective rejectionassociated transcripts has lessons for future studies. First, transcript associations with rejection are highly reproducible when attention is paid to case mix, disease classification, algorithm details, and technology platform, although some random variation in exact rank is expected even between highly similar populations, as shown when the population of 703 biopsies was divided in half. Second, a comprehensive case mix and multiple algorithms must be used to map the ABMRand TCMR-selective features, with adequate numbers of the other rejection type included in the negative class. Third, many abnormal but nonrejecting biopsies should be included in the negative comparator to distinguish rejection-associated features from the response to wounding. Nevertheless, the possibility of unrecognized rejection in late biopsies cannot be discounted simply because native kidneys with CKD also show similar changes. Many diseases leading to CKD have an immunologic component. This is true even for diseases like hypertension and arterionephrosclerosis, in which an initial ischemic insult exposes neoantigens that then excite a cell-mediated and antibody-mediated response. Fourth, a histologic classification accurately defining ABMR and TCMR is critical to avoid contaminating the classes that must be compared with misclassified biopsies. Finally, the sharing of molecular elements between rejection processes and the response to wounding means that using molecular measurements to diagnose rejection phenotypes should be quantitative and probabilistic, not qualitative.
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